The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has a significant role in initiating EBV-associated lymphoproliferative disease and EBV-related malignancies. In view of clinical features related to the type of EBV latency, LMP1 may influence invasiveness of EBV associated tumors categorized as types II and III as represented on nasopharyngeal carcinoma (NPC). To screen for genes associated with invasion of epithelial cells transformed by LMP1, Madin-Darby canine kidney (MDCK) epithelial cells were transformed by LMP1. Stable transfection of a LMP1 gene into MDCK cells induced morphological change from cobblestone to a long spindle-shape, reduced cell-cell adhesion and caused high cell motility. Parental MDCK cells, which form spherical cysts in three-dimensional collagen gel matrix, form branching tubules following exposure to hepatocyte growth factor (HGF). MDCK cells transformed by LMP1 showed invasive growth to form branching tubules into collagen gel without HGF-treatment. mRNA differential display and Northern hybridization identified plasminogen activator inhibitor-1 (PAI-1), urokinase type plasminogen activator (uPA) and ets1 as genes upregulated during transformation by LMP1. Expression of a dominant negative type of Ets1 in LMP1-transformed cells downregulated uPA expression and cell motility. Deletion of LMP1 cytoplasmic carboxy-terminal activating region 1 (CTAR1) domain abolished transformation, but a deletion mutant lacking CTAR2 domain still retained transforming and uPA-inducing ability. Expression of Ets1 was immunolocalized in tumor cells of NPC tissue which frequently express LMP1. Taken together, it is suggested that LMP1 induces expression of Ets1 which may contribute to invasion of NPC by stimulating cell motility and uPA expression.
Epstein-Barr virus (EBV) is a human herpesvirus associated with a number of malignancies including Burkitt's lymphoma and nasopharyngeal carcinoma (NPC) (Young and Rowe, 1992; Rickinson and Kieff, 1996). EBV transforms resting B lymphocytes in vitro resulting in the outgrowth of immortalized lymphoblastoid cell lines (Kieff, 1996; Rickinson and Kieff, 1996). Among the viral proteins expressed in immortalized cells, the nuclear antigens EBNA2, EBNA3A and EBNA3C and the latent membrane protein 1 (LMP1) are essential for growth transformation and immortalization of resting B lymphocyte (Henderson et al., 1991; Liebowitz and Kieff, 1993; Kieff, 1996). LMP1 is of particular interest as it resembles a classical oncogene in its ability to induce growth transformation of certain rodent fibroblast cell lines (Baichwal and Sugden, 1988; Wang et al., 1990). The transforming effects of LMP1 are likely due to its profound effects on cellular gene expression. Expression of this viral oncogene in B-cell lines can induce many of the phenotypic changes reminiscent of the activation process initiated by EBV infection, including upregulation of CD23, CD40, CD54, bcl-2 and A20 genes (Young et al., 1988; Dawson et al., 1990; Wang et al., 1990; Henderson et al., 1991). In epithelical cells LMP1 induces expression of the epidermal growth factor receptor (EGFR) and A20 genes (Miller et al., 1995; Fries et al., 1996).
LMP1 is a 62-kDa integral membrane protein containing six transmembrane segments, 24 and 200 amino acid cytoplasmic domains at the amino and carboxy terminus, respectively. The cytoplasmic carboxy terminal region contains two signaling domains that are essential for directly mediating the gene expression changes described above. The distal domain located between amino acids 352 and 386 C-terminal activating region (CTAR)-2 is the dominant NF-κB and c-Jun N-terminal kinase (JNK) activating region of this protein. The proximal domain located between amino acids 187 and 231 (CTAR1) induces low levels of NF-κB and an effect which could be attributed to its ability to interact with the TNF-α receptor associated factors (TRAFs) (Mosialos et al., 1995; Devergne et al., 1996; Kaye et al., 1996). The proximal domain (TRAF domain) also induces expression of the EGFR through a pathway distinct from NF-κB activation alone (Miller et al., 1997), and the signaling from this domain is sufficient to drive initial proliferation of EBV-infected resting B lymphocytes (Kaye et al., 1995; Izumi et al., 1997).
LMP1 and EBNAs are needed for immortalization of the B cell. On the other hand, there are distinctive clinical features related to LMP1 expression. Tumors, which express LMP1 and thus are categorized as type II or III latency, show invasive and metastatic phenotype (Miller, 1990). Therefore, it was hypothesized that LMP1 may also influence tumor invasion and metastasis.
Ets1 is a member of Ets transcription factor family and recognizes specific nucleotides sequences with a GGAA/T core sequence (Dittmer and Nordheim, 1998). Physiologically, Ets1 is expressed in various mesodermal derivatives, such as endothelial cells and mesenchymal cells (Vandenbunder et al., 1989; Queva et al., 1993; Kola et al., 1993), but is also induced in dissociating epithelial cells, during epithelial-mesenchymal transitions occurring during early development and oncogenic transformation to acquire invasive features (Gilles et al., 1996; Fafeur et al., 1997). Expression of Ets1 in tumor cells has been found to correlate with the grade of invasiveness. Sixty four per cent of gastric adenocarcinomas and 80% of those with more invasive features showed immunostaining for Ets1, whereas normal gastric epithelium or gastric adenomas were Ets1-negative (Nakayama et al., 1996). Ets1 expression in these tumors correlated with the presence of lymph node metastasis. Ets1 expression is also associated with the invasion of astrocytic tumors (Nakada et al., 1999).
In this study we demonstrated that expression of LMP1 in Madin-Darby canine kidney (MDCK) epithelial cells reduced cell-cell adhesion and enhanced motility which resulted in an invasive growth to form branching tubules into collagen gel matrix. Ets1 expression, which is induced by LMP1, contributes in part to invasion by stimulating motility and urokinase type plasminogen activator (uPA) expression.
Transformation of MDCK cells with LMP1
MDCK cells were transfected with the LMP1 gene and stable clones were selected (Figure 1). Parental (MDCK) and MDCK cells transfected with control plasmid (neo) exhibited the characteristic cobblestone morphology. Most LMP1 transfectants lost cell-to-cell contacts and acquired long spindle-shape morphology, and two representative clones were isolated (LMP1-2 and LMP1-3) Both transformed cells grew almost equally with parental MDCK cells (data not shown). Expression of 63 kDa LMP1 proteins in transformed cells was detected by Western blotting with a monoclonal antibody against LMP1 (Figure 2). Densitometric analysis showed 1.5 and 0.7-fold levels of LMP1 expression in clone LMP1-2 and LMP1-3 as compared with that of B95-8 cells, respectively.
Tubular formation of MDCK-LMP1 cells
MDCK cells transfected with control plasmid (Figure 3a, neo) formed spheroidal cysts in the collagen gel matrix and generated branching tubules following exposure to HGF (neo+HGF) as usually seen with parental MDCK cells (Montesano et al., 1991a,b). MDCK cells transformed by LMP1 spontaneously formed branching tubules through collagen gel in the absence of HGF. The LMP1 high producer clone (LMP1-2) showed more invasive growth and formed thinner tubules than moderate producer clone (LMP1-3).
Enhanced motility of MDCK-LMP1 cells
To compare the motility of LMP1 clones with that of control MDCK cells, a wound-induced migration assay was performed (Figure 3b). Confluent monolayers of each cell clone were scrape-wounded with plastic pipet, and cells migrating into a wounded area were observed after 5 h. Control MDCK cells did not migrate away from the monolayers and the monolayer edge soon became smooth due to tight cell-cell adhesion (neo). In contrast, LMP1-transformed cells migrated into a wounded area away from the monolayer edges, and the high LMP1-producer clone (LMP1-2) migrated more extensively than the moderate clone (LMP1-3).
Genes induced by LMP1
To screen genes differentially expressed between control and LMP1-transformed MDCK cells (clone LMP1-3), mRNA differential display was performed. Plasminogen activator inhibitor-1 (PAI-1) was identified as one of the genes upregulated in transformed cells, and enhanced expression of PAI-1 mRNA was confirmed by Northern blotting (Figure 4, panel PAI-1). As a gene co-expressed with PAI-1, urokinase type plasminogen activator (uPA) mRNA expression was examined by Northern hybridization, and also seen to be upregulated in transformed cells compared with parental and neo-transfected MDCK cells (Figure 4, panel uPA) (Grondaho-Hansen et al., 1993; Foekens et al., 1994). Ets1 is known to be one of the major factors regulating transcription of the uPA gene (Stacey et al., 1995; D'Orazio et al., 1997; Watabe et al., 1998), and thus ets1 mRNA expression was compared between control and LMP1-transformed MDCK cells by Northern hybridization (panel ets-1). Expression of ets1 mRNA, which was very low in parental and neo-transfected MDCK cells, was also upregulated in proportion to LMP1 mRNA level in MDCK cells transformed by LMP1.
Ets1 is associated with cell motility
To examine the role of Ets1 in transformation of MDCK cells by LMP1, a dominant negative form of Ets1 (Ets-DN) was expressed in transformed cells. As expectedly, stable expression of Ets-DN downregulated synthesis of uPA mRNA in the LMP1-transformed MDCK cells (Figure 5). However, LMP1-transformant expressing Ets-DN still retained a long spindle-shape morphology and showed reduced cell-cell adhesion (Figure 6). In the wound-induced migration assay, expression of Ets-DN downregulated migration of transformed cells into wounded area, but cells at leading edge did not adhere to each other tightly as seen in parental MDCK cells (see Figure 3).
Transformation requires LMP1 CTAR1 region
Previously two domains in the carboxy-terminus of LMP1 have been identified to be important for NF-κB activation, the CTAR-1 (residues 194–232) and CTAR-2 (residues 351–386) (Huen et al., 1995; Kaye et al., 1995). To explore the mechanism of transformation by LMP1, LMP1 deletion mutants were stably transfected into MDCK cells and their transforming ability was compared (Figure 7). Expression of LMP1 mutant lacking CTAR1 domain (Δ187–351) failed to transform MDCK cells, but cells expressing a mutant lacking CTAR2 domain (1–231) showed transformed morphology and high motility in wound-induced migration assay.
Overexpression of Ets1 in NPC
Expression of Ets1 in NPC tissue, in which LMP1 was frequently expressed, was analysed by immunostaining with a monoclonal antibody against Ets1 (Figure 8). Tumor cells in a NPC tissue were positively immunostained with a monoclonal antibody against Ets1. Ets1 antigen was not restricted to nuclei but whole cells were stained. LMP1 was immunolocalized primarily on cell membrane of tumor cells in the NPC tissue.
LMP1 has a significant role in initiating EBV-associated lymphoproliferative disease and EBV-related malignancies (Young and Rowe, 1992; Liebowitz and Kieff, 1993). In view of its association with clinical features related to type of latency, LMP1 may influence invasiveness of EBV associated tumors categorized as types II and III. Tumor invasion consists of three major steps, e.g. adhesion, degradation and motility (Liotta, 1992). In this study we demonstrated that transformation of MDCK cells by LMP1 resulted in morphological change, reduced cell-cell adhesion and high motility. MDCK cells, which form spherical cysts in three-dimensional collagen gel matrix, form branching tubules following exposure to HGF (Montesano et al., 1991a,b). MDCK cells forming branching tubules share some of the properties of metastatic tumor cells, such as reduced cell-cell adhesion, high motility and degradation of extracellular matrix components including type I collagen. MDCK cells transformed by LMP1 spontaneously formed branching tubules in collagen gel without HGF treatment. Transformation of MDCK cells by LMP1 resulted in morphological changes similar to that observed with HGF treatment. Thus, expression of LMP1 gene in MDCK cells has a similar effect to HGF treatment. In this study we observed induction of PAI-1, uPA and ets1 gene expression during transformation of MDCK cells by LMP1, and interestingly HGF-treatment of MDCK cells also stimulated expression of these genes (Fafeur et al., 1997). In response to HGF, the intracellular portion of the c-Met proto-oncogene receptor becomes autophosphorylated and binds to a number of proteins, including phosphatidylinositol 3-kinase, phospholipase, Cγ, pp60c-src, Grb-2, SHC, and GAB1 (Bardelli et al., 1992; Ponzetto et al., 1994; Pelicci et al., 1995). The CTAR1 domain of LMP1, which was reported to induce expression of EGFR through the TRAF signaling pathway (Mosialos et al., 1995; Devergne et al., 1996; Kaye et al., 1996), was responsible for transformation of MDCK cells. However, the CTAR2 domain, which is the dominant NF-κB and JNK activating region (Huen et al., 1995; Kaye et al., 1995; Eliopoulos and Young, 1998), was not essential for transformation of MDCK cells. The signaling from CTAR1 domain is also essential and sufficient to induce initial proliferation of EBV-infected resting B lymphocytes (Kaye et al., 1995; Izumi et al., 1997). It still remains to be solved which transduction pathway is activated by the CTAR1 domain of LMP1, which shares a common effect with signaling from c-Met HGF receptor.
LMP1 reportedly reduces expression of E-cadherin in a keratinocyte cell line (Fahraeus et al., 1990), however, the cell dissociation caused by HGF-treatment is not due to downregulation of E-cadherin expression but due to counteraction of junctional assembly through tyrosine-phosphorylation of the E-cadherin-catenin complex (Nabeshima et al., 1998; Grisendi et al., 1998; Davies et al., 1999; Hiscox and Jiang, 1999). Considering the similar morphological effects caused by HGF-treatment and LMP1 transformation, reduced cell-cell adhesion caused by the expression of LMP1 is more likely due to phosphorylation of E-cadherin-catenin complex.
Expression of Ets-DN in MDCK cells transformed by LMP1 resulted in downregulation of uPA expression and cell motility. These results suggest that among various phenotypical changes induced by LMP1 expression, regulation of uPA gene expression and enhanced cell motility are mediated at least in part by Ets1. Since the uPA gene promoter contains a binding site for Ets, and Ets1 is a major transcription factor regulating uPA gene expression, enhanced expression of uPA gene in transformed cells is largely attributed to overexpression of Ets-1 (Watabe et al., 1998; D'Orazio et al., 1997; Stacey et al., 1995). uPA is a serine protease and contributes to tumor invasion by degrading extracellular matrix components, and thus its expression is widely correlated with tumor metastasis (Testa and Quigley, 1990; Bindal et al., 1994). PAI-1 is an inhibitor of uPA, but paradoxically expression of PAI-1 also correlates with tumor metastasis (Sappino et al., 1991; Grondaho-Hansen et al., 1993; Foekens et al., 1994). As described above, expression of PAI-1, uPA and ets1 genes is induced in MDCK cells by HGF treatment, however, induction of PAI-1 gene expression takes place earlier than that of uPA and ets1 genes (Fafeur et al., 1997). This suggests that Ets1 does not directly regulate expression of PAI-1 gene.
Although Ets1 has oncogenic potential in mice, there is no direct evidence that it plays a role in oncogenesis in human. However, Ets1 expression in tumor cells has been found to correlate with the grade of invasiveness in human tumor tissues (Nakayama et al., 1996; Nakada et al., 1999) and correlates with a degree of invasiveness in breast cancer cell lines (Gilles et al., 1996). A high level of expression of Ets1 was detected by immunostaining in NPC tissue specimen, where it may stimulate expression of genes associated with invasion. The mechanism of regulating cell motility by Ets1 is not fully understood. Ets family members were reportedly involved in the control of cell motility and invasion during normal tubular morphogenesis and cancerous scattering in mammary epithelial cells (Delannoy et al., 1998). Recently we found that metastasis associated mts1/S100A4 calcium binding protein is implicated in motility of MDCK cells during tubulogenesis and oncogenic transformation (submitted for publication) and will examine whether expression of mts1 gene is controlled by Ets1 or not.
Previously, we reported that LMP1 stimulated expression of matrix metalloproteinase-9 (MMP-9), which is implicated in tumor invasion and metastasis by degrading type IV collagen, a major component of basement membrane (Yoshizaki et al., 1998; Takeshita et al., 1999). Expression of MMP-9 gene was at a very high level in parental MDCK cells and was not further stimulated by transformation with LMP1 (data not shown). However, the MMP-9 gene promoter contains a binding site for Ets in addition to AP-1 and NF-κB (Sato et al., 1992), and thus Ets1 may positively regulate MMP-9 gene expression in different cell lines (Watabe et al., 1998). Therefore, Ets1 may stimulate transcription of many genes associated with tumor invasion and metastasis, and would be an effective target in preventing invasion of EBV-associated tumors.
Materials and methods
Plasmids and expression vectors
The pcDNA3 eukaryotic expression vector (Invitrogen, Carlsbad, USA) which contains the CMV immediate early promoter and neomycin resistant gene was used for the LMP1 expression constructs. Expression plasmids for LMP1 mutants were described previously (Takeshita et al., 1999).
The cDNA sequence encoding Ets-DN, which lacks transcription activation domain and corresponds to amino acids residues 306–441, was obtained by PCR amplification of human Ets-1 cDNA. The cDNa fragment thus obtained was inserted behind the ATG start codon introduced into pCEP4 expression plasmid, which contains hygromycin resistant gene (Invitrogen) (Nakada et al., 1999).
Cell lines and stable transfection
MDCK cells were obtained from Health Science Resources Bank (Osaka, Japan) and cultured in Dulbecco's MEM (DMED) supplemented with 5% fetal calf serum (FCS). MDCK cells stably expressing LMP1 and its mutants were generated by transfecting pcDNA3 plasmid containing each cDNA fragment as described previously (Kadono et al., 1998a). Transfected MCDK cells were cultured in the presence of 600 μg/ml of G418, and several clones were isolated using stainless Peniciline cups 10 days after G418 selection. MDCK cells expressing LMP1 were transfected with pCEP4 plasmid containing Ets-DN cDNA fragment, and were selected under 800 μg/ml hygromycin B for 10 days.
Western blotting to detect LMP1 protein was carried out as described previously using a monoclonal antibody against LMP1 (gift from LA Young) (Kadono et al., 1998a). Densitometric scanning of the data was analysed by 1NIH Image.
Total RNA was extracted from MDCK cells transfected with control plasmid or pcDNA3-LMP1 plasmid by the guanidine isothiocyanate method. PolyA RNA was selected by oligo dT cellulose column chromatography. cDNA was synthesized using FITC-labeled GT12N oligo DNA as primers, where N represents A, C or G, and then PCR amplification of cDNA was done using FITC-labeled GT12N and 10 mer arbitrary oligo primers (Noritake et al., 1999). PCR products were separated on 4 and 6% polyacrylamide gels and were analysed by FluorImager 585 (Molecular Dynamics, Sunnyvale, USA). PCR fragments differentially amplified were picked up from the gels and were further PCR amplified with unlabeled primers. Amplified fragments were labeled with 32P and used as probes for Northern hybridization to confirm the differential expression of the gene.
A cDNA library was constructed using a Uni-ZAP XR vector kit according to the manufacturer's instruction (Stratagene, La Jolla, USA). Screening of the library was performed using 32P-labeled PCR fragments obtained as above. Nucleotide sequences were determined by automated sequencer Model 373A (Applied Biosystems, Foster City, USA).
Total RNA samples (5 μg) extracted from control and LMP1 MDCK cells were separated by electrophoresis on a denaturing 1.0% agarose gel and transferred onto to nylon membrane Hybond-N (Amersham, Buckinghamshire, UK). Hybridization and preparation of 32P-labeled probes were carried out as described previously (Kadono et al., 1998). Radioactivity was analysed by a Bioimage Analyzer BAS 1000 (Fuji Photo Film Co., Tokyo, Japan).
Collagen gel culture
To make the collagen mixture, seven volumes of ice cold type I collagen stock solution (Nitta Gelatin, Osaka, Japan) as mixed with two volumes of 5× concentrated DMEM and one volume of 0.05 N NaOH containing 2.2% NaHCO3, and 200 mM HEPES. Cells were suspended in the collagen mixture at 5×104 cells/ml and incubated at 37°C for 30 min until the mixture was allowed to gel, and was then overlayed with standard medium. Cells were incubated with 50 ng/ml recombinant human HGF (TOYOBO, Osaka, Japan).
Scrape-wound migration assay
Confluent monolayers of control LMP1 MDCK cells were scraped by plastic pipet and cells migrating into the scraped area were observed after 5 h.
Immunolocalization of Ets1 and LMP1 in the NPC tissues
Tissue samples of NPC were fixed with paraformaldehyde, and the paraffin sections were immunostained using the monoclonal antibodies to Ets1 (Santa Cruz, Santa Cruz, USA) and LMP1.
Baichwal VR and Sugden B . 1988 Oncogene 2: 461–467
Bardelli A, Maina F, Gout I, Fry MJ, Waterfield MD, Comoglio PM and Ponzetto C . 1992 Oncogene 7: 1973–1978
Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R and Rao JS . 1994 J Neurooncol 22: 101–110
D'Orazio D, Besser D, Marksitzer R, Kunz C, Hume DA, Kiefer B and Nagamine Y . 1997 Gene 201: 179–187
Davies G, Jiang WG and Mason MD . 1999 Anticancer Res 19: 547–552
Dawson CW, Rickinson AB and Young LS . 1990 Nature 344: 777–780
Delannoy CA, Mattot V, Fafeur V, Fauquette W, Pollet I, Calmels T, Vercamer C, Boilly B, Vandenbunder B and Desbiens X . 1998 J Cell Sci 111: 1521–1534
Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E and Mosialos G . 1996 Mol Cell Biol 16: 7098–7108
Dittmer J and Nordheim A . 1998 Biochimica et Biophysica Acta 1377: 1–11
Eliopoulos AG and Young LS . 1998 Oncogene 16: 1731–1742
Fafeur V, Tulasne D, Queva C, Vercamer C, Dimster V, Mattot V, Stehelin D, Desbiens X and Vandenbunder B . 1997 Cell Growth Differ 8: 655–665
Fahraeus R, Rymo L, Rhim JS and Klein G . 1990 Nature 345: 447–449
Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MO, Janicke F and Klijin JGM . 1994 J Clin Oncol 12: 1648–1658
Fries KL, Miller WE and Raab TN . 1996 J Virol 70: 8653–8659
Gilles F, Raes MB, Stehelin D, Vandenbunder B and Fafeur V . 1996 Exp Gcll Res 222: 370–378
Grisendi S, Arpin M and Crepaldi T . 1998 J Cell Physiol 176: 465–471
Grondaho-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M . 1993 Cancer Res 53: 2513–2521
Henderson S, Rowe M, Gregory C, Croom CD, Wang F, Longnecker R, Kieff E and Rickinson A . 1991 Cell 65: 1107–1115
Hiscox S and Jiang WG . 1999 Anticancer Res 19: 509–517
Huen DS, Henderson SA, Croom CD and Rowe M . 1995 Oncogene 10: 549–560
Izumi KM, Kaye KM and Kieff ED . 1997 Proc Natl Acad Sci USA 94: 1447–1452
Kadono Y, Okada Y, Namiki M, Seiki M and Sato H . 1998a Cancer Res 58: 2240–2244
Kadono Y, Shibahara K, Namiki M, Watanabe Y, Seiki M and Sato H . 1998b Biochem Biophys Res Commun 251: 681–687
Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E and Mosialos G . 1996 Proc Natl Acad Sci USA 93: 11085–11090
Kaye KM, Izumi KM, Mosialos G and Kieff E . 1995 J Virol 69: 675–683
Kieff E . 1996 Virology, Fields BN, Knipe DM and Howley PM eds. 3rd edn Lippinscott-Raven Publishers Philadelphia, PA pp 2343–2396
Kola I, Brookes S, Green AR, Garber R, Tymms M, Papa TS and Seth A . 1993 Proc Natl Acad Sci USA 90: 7588–7592
Liebowitz D and Kieff Y . 1993 The human herpesviruses Roizman B, Whitley RJ and Lopez C eds. Raven Press Ltd NY pp 107–172
Liotta LA . 1992 Sci Am 266: 54–59
Miller G . 1990 Virology, Fields BN and Knipe DM eds. 2nd Ed Lippinscott-Raven Publishers Philadelphia, PA pp 1921–1958
Miller WE, Earp HS and Raab TN . 1995 J Virol 69: 4390–4398
Miller WE, Mosialos G, Kieff E and Raab TN . 1997 J Virol 71: 586–594
Montesano R, Schaller G and Orci L . 1991a Cell 66: 697–711
Montesano R, Matsumoto K, Nakamura T and Orci L . 1991b Cell 67: 901–908
Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C and Kieff E . 1995 Cell 80: 389–399
Nabeshima K, Shimao Y, Inoue T, Itoh H, Kataoka H and Koono M . 1998 Int J Cancer 78: 750–759
Nakada M, Yamashita J, Okada Y and Sato H . 1999 J Neuropathol Exp Neurol 58: 329–334
Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Fagin JA, Yamashita S and Sekine I . 1996 Am J Pathol 149: 1931–1939
Noritake H, Miyamori H, Goto C, Seiki M and Sato H . 1999 Clinic Exp Met 17: 105–110
Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG et al. 1995 Oncogene 10: 1631–1638
Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla ZP, Giordano S, Graziani A, Panayotou G and Comoglio PM . 1994 Cell 77: 261–271
Queva C, Leprince D, Stehelin D and Vandenbunder B . 1993 Oncogene 8: 2511–2520
Rickinson A and Kieff E . 1996 Virology, Fields BN, Knipe DM and Howley PM eds. 3rd Edn Lippinscott-Raven Publishers Philadelphia, PA pp 2397–2446
Sappino AP, Belin D, Huarte J, Hirschel SS, Saurat JH and Vassalli JD . 1991 J Clin Invest 88: 1073–1079
Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J and Seiki M . 1992 Oncogene 7: 77–83
Stacey KJ, Fowles LF, Colman MS, Ostrowski MC and Hume DA . 1995 Mol Cell Biol 15: 3430–3441
Takeshita H, Yoshizaki T, Miller W, Sato H, Furukawa M, Pagano JS and Raab-Traub N . 1999 J Virol 73: 5548–5555
Testa JE and Quigley JP . 1990 Cancer Metastasis Rev 9: 353–367
Vandenbunder B, Pardanaud L, Jaffredo T, Mirabel MA and Stehelin D . 1989 Development 107: 265–274
Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A and Kieff E . 1990 J Virol 64: 2309–2318
Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S and Fujinaga K . 1998 Int J Cancer 77: 128–137
Yoshizaki T, Sato H, Furukawa M and Pagano JS . 1998 Proc Natl Acad Sci USA 95: 3621–3626
Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A and Rickinson AB . 1988 J GenVirol 69: 1051–1065
Young LS and Rowe M . 1992 Semin Cancer Biol 3: 273–284
We thank Dr EW Thompson for critical reading of the manuscript, Dr N Raab-Traub for expression plasmids for truncated LMP1, and Dr LA Young for the monoclonal antibody against LMP1. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan and by a grant from NOVARTIS Foundation (Japan) for the Promotion of Science.
About this article
The EBV-Encoded Oncoprotein, LMP1, Induces an Epithelial-to-Mesenchymal Transition (EMT) via Its CTAR1 Domain through Integrin-Mediated ERK-MAPK Signalling
Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma
Cancer and Metastasis Reviews (2017)
Structural and functional characteristics of the LMP1 oncogene in patients with tumors аssociated and not associated with the Epstein–Barr virus
Molecular Genetics, Microbiology and Virology (2016)
Structural and functional characteristics of the LMP1 oncogene in patients with tumors associated and not associated with the Epstein-Barr virus
Molecular Genetics Microbiology and Virology (Russian version) (2016)